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Abstract: Polymorphonuclear neutrophils (PMNs) are innate immune cells, which represent 50% to 
70% of the total circulating leukocytes. How PMNs adapt to various microenvironments 
encountered during their life cycle, from the bone marrow, to the blood plasma fraction, and to 
inflamed or infected tissues remains largely unexplored. Metabolic shifts have been reported in 
other immune cells such as macrophages or lymphocytes, in response to local changes in their 
microenvironment, and in association with a modulation of their pro-inflammatory or anti-
inflammatory functions. The potential contribution of metabolic shifts in the modulation of 
neutrophil activation or survival is anticipated even though it is not yet fully described. If 
neutrophils are considered to be mainly glycolytic, the relative importance of alternative metabolic 
pathways, such as the pentose phosphate pathway, glutaminolysis, or the mitochondrial oxidative 
metabolism, has not been fully considered during activation. This statement may be explained by 
the lack of knowledge regarding the local availability of key metabolites such as glucose, glutamine, 
and substrates, such as oxygen from the bone marrow to inflamed tissues. As highlighted in this 
review, the link between specific metabolic pathways and neutrophil activation has been outlined 
in many reports. However, the impact of neutrophil activation on metabolic shifts’ induction has 
not yet been explored. Beyond its importance in neutrophil survival capacity in response to 
available metabolites, metabolic shifts may also contribute to neutrophil population heterogeneity 
reported in cancer (tumor-associated neutrophil) or auto-immune diseases (Low/High Density 
Neutrophils). This represents an active field of research. In conclusion, the characterization of 
neutrophil metabolic shifts is an emerging field that may provide important knowledge on 
neutrophil physiology and activation modulation. The related question of microenvironmental 
changes occurring during inflammation, to which neutrophils will respond to, will have to be 
addressed to fully appreciate the importance of neutrophil metabolic shifts in inflammatory 
diseases. 
Keywords: neutrophils; energetic metabolism; infection; inflammation; nutrient availability; oxygen 
sensing 
 
1. Introduction 
Polymorphonuclear neutrophils (neutrophils, PMNs) like all migratory cells face various 
microenvironments during their lifecycle from their site of production to their site of action or 
clearance (view figure 1). Neutrophils are the most abundant leukocytes in the circulation, which 
Int. J. Mol. Sci. 2020, 21, 287 2 of 23 
 
represent 50% to 70% of circulating leukocytes. Circulating neutrophils are fully differentiated cells 
and are believed to have a relatively short lifespan, which is likely largely dependent on 
environmental parameters. Bone marrow and blood plasma homeostasis are expected to play a 
central role in maintaining neutrophils in a quiescent state under basal conditions, even though the 
parameters involved in this process remain largely undefined. In eukaryotic cells, energy is produced 
by glycolysis in the presence of glucose, mitochondrial respiration (oxidative phosphorylation) in the 
presence of oxygen, and the tricarboxylic acid (TCA) cycle, in the presence of oxygen and pyruvate, 
glutamine, or free fatty acids. Under a basal condition, neutrophils are mainly glycolytic and contain 
few mitochondria [1]. However, the contribution of mitochondrial respiration or the TCA cycle to 
neutrophil energy production has not been fully investigated upon activation. We have demonstrated 
that oxygen exposure has a deleterious effect on neutrophil viability [2–4], even though the potential 
involvement of mitochondria in this process has not been established. As a consequence, the 
respective abundance of metabolites and substrates, such as glucose, glutamine, and oxygen in the 
neutrophil microenvironment appears to be critical for neutrophil physiology, survival, and 
activation.  
This point may be illustrated by the metabolic shift occurring during neutrophil differentiation 
(granulopoiesis) from hematopoietic stem cells (HSCs) in the bone marrow. The importance of 
metabolic shifts in immune cell adaptation to their microenvironment has been extensively 
demonstrated in the polarization of tumor-associated macrophages (TAM), which allows the 
characterization of two populations: M1 and M2. M1 macrophages are mainly glycolytic with limited 
oxygen consumption capacity. In comparison, M2 macrophages mainly use oxidative 
phosphorylation for energy production. The M1/M2 metabolic shift has a functional correlation, 
where M1 exhibits a pro-inflammatory and anti-tumoral phenotype and M2 exhibits an anti-
inflammatory and pro-tumoral one [5,6]. Similar classification of tumor-associated neutrophil (TAN) 
populations has been proposed by Fridlender (namely N1/N2 populations) in response to TGF-β [7]. 
This concept is currently evaluated in different inflammatory models and is being discussed [8]. 
Although no metabolic shifts or differences have yet been reported between the N1 and N2 
populations, their identification strongly suggests that neutrophils can efficiently respond and adapt 
to local microenvironmental changes. 
The ability of neutrophils to sense and adapt to changes of microenvironmental parameters, such 
as the pO2 or the glucose concentration, is well documented through transcriptional regulations (e.g., 
HIF1-dependent and HIF2-dependent) [9]. However, the impact of neutrophil metabolic activity or 
activation on its microenvironment is likely underestimated and will be further discussed. In 
addition, it remains unclear whether heterogeneous microenvironments encountered by neutrophils 
during their lifecycle modulate and shape the population homogeneity (N1/N2 or high-density/low-
density neutrophils) if these processes are reversible or not. 
In this case, current knowledge on neutrophil metabolism under basal conditions will be 
reviewed, and potential metabolic shifts occurring within inflamed tissues or upon cell activation 
will be described. We aim to elucidate how neutrophils adapt to stressful conditions encountered 
during their lifecycle, by either tuning or modulating their metabolic pathways or using stored 
metabolites. 
2. Available Metabolites in the Bone Marrow, Plasma, and Inflamed Tissues 
Under basal conditions, blood plasma homeostasis is expected to limit neutrophil activation and 
to sustain their viability. Conversely, the inflammatory tissue microenvironment allows neutrophil 
activation (migration, degranulation, phagocytosis, or reactive oxygen species (ROS) production). 
The relative abundance of glucose, glutamine, and oxygen in plasma and in inflammatory tissues is 
reviewed hereafter (view table 1). 
2.1. Bone Marrow Homeostasis 
The bone marrow microenvironment plays a crucial role in the control of hematopoietic stem 
cell proliferation and differentiation [10]. However, to our knowledge, the concentrations of glucose 
Int. J. Mol. Sci. 2020, 21, 287 3 of 23 
 
and glutamine in this microenvironment remain unknown. Further investigations are required to 
determine these key parameters to better appreciate and understand the physiology of mature 
neutrophils stored in the bone marrow, which represent the vast majority of the neutrophil 
population. The bone marrow has long been described as a hypoxic environment, despite being 
densely perfused. This perception has been recently confirmed by local pO2 quantification in mice 
bone marrow by Spencer and colleagues using two-photon phosphorescence lifetime microscopy, 
which is a non-invasive and non-destructive quantification method [11]. In this study, the authors 
demonstrated that the bone marrow oxygenation level is heterogeneous but still rather low in all 
compartments (below 32 mmHg, or 4.2%). Surprisingly, the most hypoxic environment was 
measured in peri-sinusoidal regions (9.9 mmHg, or 1.3%), while the endosteal region was less 
hypoxic (21.9 mmHg, or 2.9%), which is being perfused by small arteries. 
2.2. Plasma Homeostasis 
Under basal conditions, the glucose level remains tightly controlled at 5.6-6.9 mM in the blood. 
These values are relatively high with regard to neutrophil glucose metabolic needs and to the 
maintenance of their viability. Hyperglycemia has been reported to have an adverse effect on 
neutrophil activation (e.g., mobilization defect) [12,13], induction of neutrophil extracellular traps 
(NET) formation [14], and inflammasome activation [15], even though no direct link with potential 
metabolic shifts has been reported. To our knowledge, the neutrophil metabolic adaptation under 
hypoglycemia has not been investigated. 
Similar to glucose, L-glutamine is well maintained in the plasma at a 0.4–0.6 mM concentration. 
Being the most abundant amino acid in the body, it fuels the production of the most abundant 
intracellular amino acid L-glutamate [16]. A constant glutaminemia is crucial for proper functioning 
of the immune system. Compared to hyperglycemia or hypoglycemia, neither changes in 
glutaminemia in plasma, nor its impact on a potential neutrophil metabolic shift have yet been 
investigated.  
The plasma oxygen level is contained at very low concentrations, as described by Pittman [17]. 
Since 98% of oxygen is transported by red blood cells, the dissolved fraction represents only 2%. 
Plasma oxygenation has never been quantified in situ due to technical and ethical limitations. Based 
on a theoretical calculation of plasma oxygenation (Henry’s law of gas diffusion), it is estimated that 
plasma pO2 varies between 1.4 mmHg in veins and 2 mmHg in arteries (with pO2 vein=70 mmHg, and 
pO2 artery = 100 mmHg). Taken these values together with the high amount of glucose in plasma, it is 
anticipated that the glucose metabolism will be favored for the oxidative metabolism in circulating 
neutrophils (see below). 
pH in the plasma is strictly maintained between 7.35 and 7.45 via large amounts of carbonic acid 
and bicarbonate. 
2.3. Tissue Homeostasis 
Glucose passively diffuses from the blood plasma to organs to ensure that the supply meets the 
needs under basal conditions. Apart from getting nutritional glucose, some organs, such as the liver 
and muscles, can store glucose in the form of glycogen (100 g and 400 g, respectively). Circulating 
neutrophils are known to rely on glycolysis to maintain their viability and function [1,18,19]. 
Glycogen bodies have been observed in quiescent neutrophils (electron microscopy) [20,21] as well 
as the presence and expression of glycogen synthase (Gly1), which is necessary for glycogen synthesis 
[22]. The intracellular glycogen concentration in quiescent neutrophils is estimated at  
1 µg/1.106 cells [22]. 
Glutamine is a non-essential amino acid. However, it may be considered conditionally essential 
during illness since intestines and the immune system utilize a large amount of glutamine during 
inflammation, which exceeds endogenous production. The glutamine concentration in tissues under 
basal conditions is relatively poorly known and is estimated to be higher than in the plasma fraction 
(intracellular concentration 2–20 mM). For example, the measurements performed in human muscles 
indicated a glutamine concentration ranging from 2–4 mmol/L [23]. In rat hepatocytes, intracellular 
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glutamine was even higher, measured at 7mM [24]. In mice, basal glutamine concentration in the 
plasma is around 0.2 mM in organs such as the liver and the kidney at 2.8 and 0.5 µmol/g, respectively 
[25]. 
The importance of glutamine concentration during inflammation remains elusive and will be 
discussed in the next chapter. 
The basal level of oxygen in tissues is organ-specific and depends on the local supply and 
metabolic needs. Physiological O2 concentration has been defined as “physioxia” [26,27] and ranges 
from 1% to 11% in human body compartments [28,29]. 
Similar to oxygen, pH values tend to vary between different tissue types, whereas skeletal 
muscle tissue’s pH is 6.8–7.1, colon tissue’s pH is 7.9–8.5, and small intestine tissue’s pH is 7.2–7.5. 
2.4. Available Metabolites in the Inflamed Tissue Microenvironment 
Not much is known about changes in the glucose concentration and local distribution in tissues 
during sterile inflammation. However, during infection, some intracellular pathogens, such as 
Salmonella and Brucella consume glucose, which alters its homeostasis in tissues [30,31]. In the case of 
Brucella infection, a two-fold decrease of intracellular glucose was measured in murine macrophages 
(from 1 to 0.5 µM, respectively) [31], and reduces the glucose supply during Listeria monocytogenes 
infection, which increases the mice survival rate [32]. 
Many studies report the benefit of glutamine supplementation on intestinal inflammation. In 
general, glutamine sustains enterocyte proliferation, suppresses pro-inflammatory pathways, and 
protects host cells from apoptosis, among other functions [33]. Under continuous stress conditions, 
muscles and lungs are known to release glutamine, since other organs increase glutamine uptake and 
consumption. In human tissues, the intracellular glutamine concentration decreases compared to 
murine tissues where a two-fold increase in glutamine concentration was observed in plasma and 
tissues samples during stress conditions. Measurements done in patients with chronic inflammatory 
stress, causing intestinal permeability, showed a correlation between the severity of inflammation 
and decreased glutamine levels in human intestines (mucosa) and plasma [34]. In this particular 
study, tissue glutamine concentration of inflammatory mucosa ranged from 1.4 to 4 mM, whereas 
higher values were measured in patients with low inflammation markers [34]. A decrease of 
glutamine concentration was associated with inflammatory activity rather than nutritional depletion, 
which suggests an increase in local glutamine consumption. Values of glutamine fluctuations in case 
of infection are not well known. However, it was recently shown that Escherichia coli can use 
glutamine during infection, which mediates their protection from acid stress and copper ion toxicity, 
which lowers the local glutamine concentration [35]. 
It is well accepted that the local oxygen level decreases during inflammation, as first 
demonstrated in a colitis mouse model by Karhausen and colleagues [36]. This observation has been 
further confirmed by other groups, which leads to the concept of “inflammatory hypoxia” [37]. 
Recently, our group demonstrated a severe hypoxia induction during Shigella infection in the guinea 
pig colon, which refers to the “infectious hypoxia” concept [38]. The main cause of hypoxia induction 
is the consumption of oxygen by the bacteria aerobic respiration [39]. Similar observations have been 
seen during Staphylococcus aureus [40] (reviewed by Hajdamowicz et al. [41]) and Salmonella 
typhimurium infections [42] or upon Mycobacterium tuberculosis granuloma formation [43]. 
Similar to pathogens, tumor cells are capable of shaping the local microenvironment to promote 
their growth and survival. 
Cancer cells are usually characterized by a high glycolytic phenotype, which produces lactate 
and lowers the extracellular pH in the tumor microenvironment (TME). However, tumors can have 
a glycolytic (mainly) or an oxidative metabolism. TMEs of each phenotype differ in nutrient 
availability. Some parameters are similar in both, such as hypoxia (<2%) and acidosis (pH 6.5–6.9) 
[44], which are considered potential cancer drug targets (reviewed by Bailey et al. [45]). The glycolytic 
tumor cell metabolism is highly impacted by the stabilization of the hypoxia-inducing factor (HIF) 
pathway, which upregulates glycolysis. Glycolytic tumors have a higher glucose consumption rate, 
compared to other cells present in the TME [46]. Therefore, glycolytic TMEs are characterized by low 
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glucose availability, high lactate concentration, and high acidity. On the other hand, oxidative TMEs 
are characterized by low fatty acid, amino acid, and oxygen availability (reviewed by Scharping and 
Delgoffe [47]). 
In addition to consuming most of the glucose in the TME, glycolytic tumor cells were shown to 
have an increased glutamine metabolism. It is, therefore, not surprising that glutamine levels in the 
TME are low [48–50]. However, a recent publication challenged the importance of glutamine in tumor 
metabolism by demonstrating that glutamine consumption was not increased and remained 
relatively low in in vivo mouse lung cancer models [51]. These opposing findings finely illustrate the 
heterogeneity of tumor cell metabolism and potential biases occurring during in vitro experiments.  
Tumor hypoxia is perceived as a deleterious factor in cancer therapy. Hypoxia within the tumor 
varies and creates a gradient of 0.1–6% O2, depending on the size and the vascularization of the tumor 
[52]. Despite the fact that hypoxia induction has been reported in various inflammatory models, no 
pO2 quantification has yet been achieved in situ with non-disruptive quantification methods. This 
likely represents one of the most challenging goals in the field. 
pH values during inflammation tend to differ dramatically from homeostatic values. 
Inflammation sites are characterized by a drop in pH rather than an increase. The acidification is 
linked to the glycolytic metabolism of infiltrating immune cells in case of infection and to the 
glycolytic metabolism of cancer cells in tumor microenvironments, which produces and releases 
lactic acid. 
3. Neutrophil Metabolism 
The most thoroughly described metabolism in neutrophils is glycolysis since circulating 
neutrophils are considered to be highly glycolytic under physiological conditions (view Figure 2). 
However, additional metabolic pathways have been described in neutrophils, such as the pentose 
phosphate pathway (PPP), The Krebs/Tricarboxylic (TCA) cycle, oxidative phosphorylation 
(OXPHOS), and a fatty acid oxidation (FAO) pathway (view Figure 2). 
3.1. Glucose Metabolism: Glycolysis and Pentose Phosphate Pathways 
Neutrophils rely on intracellular glucose shuffling to fuel their glucose-dependent metabolisms: 
glycolysis and PPP. 
Glucose shuffling per se consists in G6P/glucose cycling through the G6P transporter 
(G6PT)/G6Pase-beta complex. Shortly, G6P is imported into the endoplasmic reticulum (ER) via the 
G6PT, where it is hydrolyzed back into glucose by the G6Pase-β. Glucose can return to the cytoplasm 
where it is immediately converted back into G6P. This pathway, which limits available G6P in the 
cytoplasm, ensures tight control over the glucose metabolism fluxes.  
Defects in neutrophil glucose cycling result in decreased glucose uptake and lower intracellular 
G6P, but also impaired energy metabolism [53–56]. 
Several pathologies linked to defects in G6P/glucose cycling have been described, such as the 
glycogen storage disease type Ib (GSDIb, deficiency in G6PT) and severe congenital neutropenia 
syndrome (SCN4, deficiency in G6Pase-β). Patients with these pathologies suffer from neutropenia 
and neutrophil dysfunctions due to glycolysis inhibition [57], which highlights the importance of the 
glucose metabolism for neutrophil survival and functioning. 
Glycolysis is a ubiquitous energy metabolism, which does not differ between cell types. 
Extracellular glucose is imported into human neutrophils via glucose transporter 1 (GLUT1), which 
is expressed basally and upregulated in glucose-rich environments [57]. Other glucose transporters, 
such as 3 and 4, are also expressed but poorly described in neutrophils. If, in humans, upon activation 
with phorbol 12-myristate 13-acetate (PMA), only glucose transporter (GLUT) 1 and GLUT3 are 
upregulated [58,59], then in rats, increased GLUT4 expression has also been described when activated 
by the platelet activation factor [60]. Upon uptake, glucose is immediately transformed into glucose-
6-phosphate (G6P) by the hexokinase, where localization may be modulated by the neutrophil 
activation status [61]. The consumption of each G6P molecule will lead to the production of two 
molecules of pyruvate, two molecules of ATP, and two molecules of NADH. In aerobic conditions, 
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pyruvate can be oxidized in mitochondria through the TCA cycle (see below). However, in 
neutrophils, pyruvate is converted into lactate, which enables the regeneration of NAD+ essential for 
the continuity of glycolysis [1,18,62]. 
Another glucose-dependent pathway in neutrophils is the PPP, which is also known as the 
hexose monophosphate shunt, that has been studied in quiescent neutrophils and during activation 
(NET formation) [63]. The PPP encompasses an oxidative and a non-oxidative phase. During the 
oxidative phase, G6P-dehydrogenase (G6PD), 6-phosphogluconolactonase, and 6-phosphogluconate 
dehydrogenase convert G6P into CO2, ribulose-5-phosphate, and nicotinamide adenine dinucleotide 
phosphate (NADPH). NADPH production is essential for the maintenance of the redox balance 
under stress situations. During the non-oxidative phase, several enzymes will be involved: the ribose-
5-phosphate isomerase, the ribulose-5-phosphate 3-epimerase, a transketolase, and a transaldolase, 
which leads to the conversion of ribulose-5-phosphate into nucleic acids, sugar phosphate precursors, 
or glycolytic precursors, such as fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (G3P). 
Thus, PPP and glycolysis share a pool of G3P and F6P yielding in lactate or pyruvate. 
In neutrophils, PPP-dependent NADPH production was shown to be essential for the cytosolic 
NADPH oxidase (NOX)-dependent ROS production for NET induction [63]. In addition, inhibition 
of the PPP key enzyme, G6PD, in high glucose concentrations, was also shown to reduce superoxide 
production [64]. In leukocytes, NADPH produced via the PPP is essential for catalase positive 
bacteria killing [65]. Cooper et al. reported in an old case-study that neutrophils from a patient lacking 
G6PD with a functional NOX had deficient bactericidal functions [65]. However, further 
investigations are required to fully appreciate the contribution of PPP to neutrophil survival and 
antimicrobial activity. 
Even if neutrophils are known to rely mainly on glycolysis, the glycolytic flux is often measured 
by the consumption of glucose and production of lactate. However, as seen previously, glucose 
consumed by the PPP can equally yield lactate production. Therefore, the importance of glycolysis 
has potentially been overestimated, especially during neutrophil activation. 
3.2. Glutamine Metabolism 
Under physiological conditions, glutamine is used to produce precursor nucleotides for RNA 
and DNA synthesis. The metabolization of glutamine results in glutamate, aspartate, lactate, and 
ammonia production. 
Nevertheless, under pathophysiological conditions, when glucose supply is limited, cells, 
including neutrophils, can switch to the utilization of glutamine to meet their energetic need  
[16,66–69]. In short, glutamine can enter the cell via several solute carrier type transporters (SLCs), 
such as the sodium‐coupled neutral amino acid transporter (SNAT) family proteins. After entering 
the cytosol of neutrophils (and macrophages), glutamine is not fully oxidized and is converted into 
glutamate. Glutamate enters the mitochondria and is converted to α-ketoglutarate, which oxygenates 
NAD+ into NADH. α-ketoglutarate can enter the TCA cycle (see below) and produce malate, which 
is then converted to pyruvate via the malate dehydrogenase, which oxygenates NADP+. Pyruvate is 
then converted into lactate in the cytosol or contributes to the oxidative metabolism (OXPHOS) in the 
mitochondria. However, in low oxygen conditions (characteristic to inflammation), NAD+ can be 
regenerated through the production of lactate. Yet, how cytosolic NAD+ gets into mitochondria is not 
well established, especially since mammalian mitochondria do not synthesize NAD+ and are 
considered impermeable to pyridine nucleotides. It was recently demonstrated that cytosolic NAD+ 
or NADH can be directly transported into mammalian mitochondria. Yet, the transport mechanism 
as the transporter itself remains unknown [70].  
Interestingly, in neutrophils, glutamine can be used in higher rates than glucose [71]. Similar to 
PPP, glutaminolysis plays a role in the production of NADPH and the expression of the NOX 
complex [72]. In fact, in differentiated cells, such as macrophages and neutrophils, glutamine mainly 
plays a role during activation. It has been demonstrated that the glutamine consumption rate is highly 
increased under catabolic conditions. 
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3.3. Mitochondrial Metabolism: TCA cycle, OXPHOS, and Fatty Acid Oxidation 
Mitochondria are involved in many metabolic and cellular functions, such as cell death 
(apoptosis, pyroptosis), calcium and iron homeostasis, heme biosynthesis, and energy production. 
As discussed previously, under basal conditions, mitochondria do not contribute significantly to 
neutrophil energy metabolism and participate only in the initiation of apoptosis [1]. However, recent 
findings suggest a potential metabolic shift during activation due to changes in the 
microenvironment, which favor an oxidative metabolism and are described in many neutrophil 
subpopulations (discussed in chapter 5). 
ATP is generated via three major pathways: glycolysis, the tricarboxylic acid (TCA) cycle, and 
oxidative phosphorylation (OXPHOS).  
The TCA cycle produces OXPHOS intermediates from acetyl-CoA oxidation, which are derived 
from sugars, fats, or amino acids. OXPHOS produces ATP via a series of oxidation-reduction 
reactions, which creates a membrane electrochemical potential (∆Ψm). The ∆Ψm is generated through 
the coupling of electron transfer and H+ pumping via four complexes (C) in the mitochondrial inner 
membrane. These complexes are CI (NADH- ubiquinone oxidoreductase), CII (succinate-ubiquinone 
oxidoreductase), CIII (ubiquinol-cytochrome c oxidoreductase), and CIV (cytochrome c oxidase). 
Complex I, III, and IV are the proton pumps, which transfer protons out of the mitochondrial matrix 
and generates ∆Ψm. Although controversial, it has been shown that the mitochondrial respiratory 
chain complexes can form supercomplexes [73], containing several copies of CI, CIII, and CIV within 
one respiratory chain. The association of four or more copies of CIV was shown to enhance 
significantly the efficiency of CI and CIII to transfer electrons [74,75], which creates an increased 
membrane potential and produces more ATP. It was suggested that the lack of supercomplexes in 
circulating neutrophils may be the cause of a defective OXPHOS contribution to energy production 
under physiological conditions [61]. In neutrophils, ∆Ψm was shown to be mainly maintained via the 
transfer of electron from glycolysis to CIII, via the glycerol-3-phosphate (G3P) shuttle [62]. G3P is a 
product of glucose metabolism that can enter mitochondria where it is re-oxidized on the outer 
surface of the inner mitochondrial membrane. Although, in most cells, a membrane potential is 
coupled to ATP synthesis, it seems to differ in circulating neutrophils [62].  
Fatty acid oxidation (FAO) is essential for the production of several enzymes, hormones, and 
cell membrane components. In the cytosol, fatty acids are converted by the acyl-CoA synthetases into 
fatty acyl-CoA esters, which enter the mitochondria for subsequent oxidation. FAO consists of four 
enzymatic reactions: dehydrogenation, hydration, another dehydrogenation, and thiolysis, which 
results in one acetyl-CoA molecule, NADH, H+, FADH2, and a fatty acyl-CoA ester. After the first 
reaction, the fatty acyl-CoA ester is shortened by two carbon atoms and can return to the FAO 
pathway, where it will be re-oxidized until only two acetyl-CoA molecules remain. Acetyl-CoA then 
enters the mitochondrial TCA cycle where it will be oxidized into CO2 and H2O, generating additional 
FADH2 and NADH, H+. Electrons from both beta-oxidation and the TCA cycle can then be used by 
the OXPHOS system to generate ATP.  
To sum up, the role of mitochondrial oxidative metabolism in the function and activation of 
neutrophils has become more relevant in recent years due to the discovery of heterogenous 
neutrophil populations. Some neutrophil key functions, which were difficult to study before, have 
now been revealed to depend on mitochondrial functions [76]. For example, neutrophil chemotaxis 
is impaired when neutrophils lack a functional membrane potential or ATP synthase [77], which 
indicates the importance of mitochondria and mitochondrial metabolism during neutrophil 
transmigration into tissues. 
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Figure 1. Neutrophil presence in the bone marrow, plasma and tissues under physiological (A) and 
under pathophysiological conditions (B). PMNs – polymorphonuclear neutrophils; HSCs – 
hematopoietic stem cells. 
Table 1. Oxygen, glucose and glutamine concentrations in the bone marrow, plasma and tissues 
under physiological conditions (upper panel) and pathophysiological conditions (lower panel). 
Physiological Conditions 
Compartment Oxygen [c] Glucose [c] Glutamine [c] 
Bone marrow 1.3–2.9% ? ? 
Plasma 0.9% 5 mM 0.5 mM 
Tissue 1–11% ? 2–20 mM 
Pathophysiological Conditions 
Compartment Oxygen [c] Glucose [c] Glutamine [c] 
Bone marrow ? ? ? 
Plasma ? ? ↓ 
Tissue ↓ ↓ ↓ 
Table 2. Metabolic pathways involved in neutrophil functions. 
Neutrophil Function Metabolic Requirements References 
Phagocytosis Glycolysis [18] 
ROS production (NOX) PPP, Glutaminolysis [63,72] 
Degranulation Glycolysis [12,150] 
NET formation PPP, Glycolysis [14,63] 
Chemotaxis/migration Glycolysis, mitochondrial metabolism [76,77,147] 
ROS—reactive oxygen species; NOX—NADPH oxidase; NET—neutrophil extracellular trap;  
PPP—pentose phosphate pathway. 
4. Changes in Metabolism 
4.1. Metabolic Shift from Hematopoietic Stem Cells to Mature Neutrophils 
Hematopoietic stem cells (HSCs, CD34+) residing in the hypoxic niche of the bone marrow 
[11,78] remain in a resting quiescent state [79,80], exhibiting low bioenergetic activity [80–82]. HSCs 
glycolytic metabolism is directly linked to the stability of HIF1α, which is an oxygen-sensitive 
transcription factor, mainly involved in the expression of glycolytic enzyme genes. HSCs can exit the 
quiescent state for the purpose of self-renewal and differentiation, which leads to their asymmetric 
division, associated with a differential mitochondrial abundance [83]. The daughter cell with a higher 
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mitochondrial content will commit to differentiation and give rise to the blood cell lineages (such as 
neutrophils), whereas the cell with lower mitochondrial content will re-enter the quiescent phase  
[83–87]. The ability of HSCs to maintain a low mitochondrial pool is now considered a hallmark of 
stemness reviewed by Papa et al. [88]. It is suggested that the importance of a differential 
mitochondrial pool between self-renewing and differentiating cells is linked to the control of ROS 
production [88]. A higher mitochondrial pool will lead to a higher energy yield but also an increased 
ROS production, both necessary for differentiation. HSCs, on the other hand, are sensitive to 
oxidative stress and show low endogenous ROS levels [89–94]. Moreover, compared to other cell 
types in the bone marrow, HSCs have an increased glycolytic capacity [80], strongly related to their 
adaptation to the hypoxic niche of the bone marrow.  
Under basal conditions, neutrophil differentiation from HSCs (granulopoiesis) leads to the 
sequential formation of myeloblasts (MBs), promyelocytes (PMs), myelocytes (MCs), 
metamyelocytes (MMs), band cells (BCs), segmented cells (SCs), and mature neutrophils (PMNs). As 
previously mentioned, HSCs are heavily dependent on glycolysis [80] to meet their energetic demand 
compared to neutrophil progenitors, which shifts their metabolism toward OXPHOS during 
differentiation. However, the reason for the initiation of the metabolic shift during differentiation, 
previously believed to be due to higher oxygen concentration, has been recently challenged. As 
discussed previously, the oxygen gradient in the bone marrow decreases in the endosteal region. 
Thus, there must be another factor other than oxygen availability influencing the metabolic shift.  
The main trigger for metabolic reprogramming during hematopoiesis, apart from differential 
oxygen availability in the bone marrow [11] is autophagy [95]. Autophagy will allow the metabolic 
shift toward FAO-OXPHOS by enabling lipid droplet breakdown, providing sufficiently free fatty 
acids [95]. The inhibition of autophagy-mediated lipid degradation or fatty acid oxidation, 
accompanied with a two-fold increase of the mitochondrial content, was shown to be sufficient to 
cause defective neutrophil differentiation. The highest autophagic activity was measured in the MB 
and MC stage, which indicates a more mitochondria-dependent metabolism during these stages [95]. 
However, the mechanism of how mature neutrophils modulate metabolic fluxes and switch their 
metabolism back to glycolysis remains to be discovered.  
4.2. Neutrophils’ Metabolic Shift from Plasma to Tissues 
After their release from the bone marrow through sinusoidal capillaries, neutrophils enter the 
plasma fraction of the blood. Circulating neutrophils are considered quiescent and have a low 
transcriptional activity [96], which does not reflect their inability to modulate gene expression during 
infection or inflammation [96,97]. 
Like HSC, neutrophils are also highly dependent on HIF-1ɑ regulation [3]. HIFs are transcription 
factors, recognized as key modulators to hypoxic stress. HIFs are heterodimers containing an oxygen-
labile ɑ cytosolic subunit and a more stable nuclear β subunit. In neutrophils, two HIF isoforms are 
known as HIF1ɑ and HIF2ɑ [3,98]. HIF1 is the major transcriptional regulator involved in the 
adaptation to low oxygen environments in terms of glycolytic enzyme expression upregulation. 
Similar to HIF1, HIF2 has an important role in neutrophils, but regulates a different set of genes [99]. 
If the main role of HIF1 is to facilitate a metabolic adaptation to a low oxygen environment, then HIF2 
is mainly involved during the inflammation resolution, which regulates apoptosis signaling 
pathways [99]. Moreover, neutrophils accumulate antioxidants, such as ascorbate (vitamin C), 
capable of reducing available oxygen in cells, which limits ROS production and oxidative damage. 
Neutrophils contain high intracellular ascorbate concentrations (1–2mM) compared to plasma 
ascorbate concentration (20–80 μM) and are known to increase their intracellular ascorbate intake 
even more during oxidative burst (10–20mM), which contributes to their chemotaxis and ROS 
generation [100]. However, high ascorbate concentrations are known to promote HIF1ɑ degradation, 
even at low (1–3%) oxygen concentrations [101,102]. This suggests that the neutrophil glycolytic 
phenotype is more likely linked to parameters, such as low oxygen, high glucose, and low energetic 
needs. 
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Upon inflammation or infection, neutrophils transmigrate into tissues (diapedesis) and will 
further evolve in various microenvironments where they will exert different functions. The metabolic 
requirements for different neutrophil functions is represented in Table 2. However, how neutrophil 
metabolism is modulated during this transition remains largely unexplored. The recruitment of 
neutrophils to inflammation sites is a multi-step process consisting of (i) a selectin-mediated rolling, 
(ii) a chemokine-induced activation, and (iii) an integrin-dependent strong adhesion followed by 
trans-endothelial migration (TEM). 
For a long time, neutrophil migration was considered unidirectional and, together with the 
adhesion cascade, has been exhaustively characterized [103–105]. However, recently, Woodfin and 
colleagues discovered that neutrophils were able to retro-transmigrate back into the circulation and 
identified junctional adhesion molecule C (JAM-C) as the key regulator of directional TEM [106]. The 
retro-trans-endothelial migration (rTEM) was thought to contribute to the dissemination of systemic 
inflammation. The existence of rTEM also raises the question whether neutrophils returning from a 
different environment would exhibit phenotypic and metabolic changes and contribute to the 
heterogeneity found in the circulating neutrophilic pool in both healthy and nonhealthy subjects. The 
heterogeneity found among neutrophils was recently reviewed by Silvestre-Roig and colleagues 
[106]. 
Not much is known about the metabolic changes occurring during migration in vivo. However, 
using a zebrafish model, the function of mitochondria was shown to play a crucial role in the 
migration fitness of neutrophils into tissues. Zhou and colleagues showed that, by creating a 
mitochondrial DNA polymerase mutant, neutrophils had an altered motility in vivo [77]. It is well 
documented that, in many migrating cells, such as cancer cells and lymphocytes, motility is induced 
with localized ATP production (reviewed by Furnish and Caino, 2019; Ledderose et al., 2018  
[107,108]). In neutrophils, it seems that it is the maintenance of the mitochondrial membrane potential 
that is crucial for migration [77], which suggests that mitochondria can drive cell migration with 
additional mechanisms, not only through ATP production. 
Another report describes the role of exogenous glutamine in neutrophils chemotaxis. The 
authors showed that glutamine administration impairs neutrophils migration during endotoxemia, 
induced by E. coli lipopolysaccharide (LPS) [110]. The migration of neutrophils was enhanced in the 
absence of glutamine, which suggests a drop in glutamine concentration during infection would 
facilitate neutrophils migration to inflammation sites. In endothelial cells, glutamine was shown to 
promote proliferation and not migration [111]. In transformed breast cells, glutamine deprivation 
enhanced inflammatory gene expression [112]. Thus, the enhanced neutrophil motility could be 
explained by an active phenotype, which is promoted by glutamine deficiency causing metabolic 
stress. Thus, the administration of glutamine during infection should be wisely reviewed since it 
seems to have potentially deleterious anti-inflammatory properties. 
The role of neutrophils in inflamed tissues differs depending on the cause of inflammation. In 
the case of infection, neutrophils will be the first line of defense, using a myriad of anti-bacterial 
mechanisms to overcome pathogen propagation. However, in the case of auto-immune diseases, such 
as systemic vasculitis, systemic lupus erythematosus, rheumatoid arthritis, and some cancer types, 
neutrophils acquire a pro-inflammatory phenotype, which induces tissue damage, cancer 
progression, and, thus, the severity of the disease. It is, therefore, important to consider a 
heterogeneity in terms of pro-inflammatory or anti-inflammatory phenotypes among neutrophil 
populations depending on the inflammation type/source and local micro-environment. 
4.3. Neutrophils Metabolic Shift upon Neutrophil Antimicrobial Functions Activation 
Several metabolic pathways have been shown to be required for neutrophil antimicrobial 
functions, as briefly reviewed below. However, the impact of antimicrobial function activation on a 
potential metabolic shift has not been reported so far and remains an important question to be 
addressed. 
Borregaard and colleagues provided the first link between metabolism and antimicrobial 
activity [18]. The authors demonstrated that resting neutrophil produce ATP mainly through 
Int. J. Mol. Sci. 2020, 21, 287 11 of 23 
 
glycolysis from glucose taken up from the surrounding medium. During phagocytosis, no significant 
change of the ATP generation rate was reported, while a fall in intracellular ATP concentration was 
observed, due to energy utilization. Consistently, it was shown that mitochondria do not play a role 
in phagocytosis regulation [19]. Nevertheless, neutrophils were also shown to use different energy 
sources for different functions, demonstrating the versatile nature of neutrophils [113].  
More recently, other anti-microbial functions, such as NADPH production via NOX and NET 
formation, were shown to be glucose-dependent and glycolysis-dependent [63,114]. The NADPH 
used by NOX originates from the PPP, which demonstrates the importance of a tightly regulated 
glucose metabolism in neutrophil functions. Moreover, hyperglycemia was shown to promote NET 
formation [14], explaining the increased number of spontaneous NETs observed in Type 2 diabetes 
mellitus patients. However, deficient NET formation has been reported in high glucose 
concentrations, describing the released NETs as unstable and containing decreased amounts of anti-
microbial peptides compared to NETs released in physiological glucose concentrations [115,116]. It 
has been suggested that high glucose concentration activates neutrophils, and hinders them to react 
to additional stimuli, such as LPS [116–118]. It is currently well accepted that hyperglycemia impairs 
many neutrophils’ key functions [119], such as phagocytosis, ROS production, and bacterial killing, 
as reviewed by Insuela and colleagues [119]. The exact mechanism involved in neutrophil 
impairment in high-glucose conditions remains to be identified. Nevertheless, since glucose 
concentration seems to be the centerpiece of neutrophil functions, the choice of the cell culture 
medium for in vitro experiments is crucial (e.g., RPMI medium contains 11 mM glucose). 
On the other hand, in the absence of extracellular glucose, ATP generation in neutrophils is 
exclusively associated with glycogenolysis, which consists of breaking down glycogen molecules 
present in the cytosol of neutrophils. It has been demonstrated that, in the absence of glucose, ATP 
generation decreases from 1.3 fmol/cell/min to 0.75 fmol/cell/min [18]. Yet, phagocytosis was shown 
to upregulate ATP generation (and glycogenolysis) up to 1.2 fmol/cell/min [18]. However, it has not 
been reported whether or not NET formation efficiency is modulated in these conditions, which raises 
the question of NET formation potential in glucose-poor environments. Moreover, the differences of 
glucose-associated anti-microbial functions in terms of efficiency and energy metabolism during 
glycogenolysis or in the presence of glucose remains to be further investigated. 
The importance of glycogen storage and utilization has been elegantly demonstrated by 
Walmsley and colleagues. The authors showed that, in the absence of Phd2, the HIF-hydroxylase, by 
inhibiting the HIF pathway activation, neutrophil functions were enhanced [22]. Moreover, hypoxia 
pre-conditioning activating HIF and increasing glucose utilization, was shown to increase the 
efficiency of neutrophils in terms of antimicrobial activity [120]. Since HIF-1 plays a crucial role in the 
adaptation to low oxygen concentrations by upregulating glycolysis, we can appreciate that the 
regulation of the glycolytic flux and glycogen storage are important during pathogen clearance but 
also during inflammation resolution [22]. Until now, no direct link between glutaminolysis or a shift 
toward this metabolic pathway upon neutrophil antimicrobial function activation has been reported. 
As previously mentioned, NET formation relies on glucose metabolism in terms of NOX activity 
(PPP) and energy production (glycolysis), which correlates with observation of Glut1 and Glut3 
upregulation upon PMA stimulation [58]. However, besides NOX-dependent NETs (ND-NETs), 
NOX-independent NETs (NI-NETs) have also been characterized. NI-NETs are induced by calcium 
ionophores, which enhances mitochondrial ROS production [121] and are, therefore, believed to be 
less dependent on glucose metabolism. Although the source of ROS differs between ND-NETs and 
NI-NETs, the difference in terms of energy metabolism has not been investigated. Moreover, oxygen 
seems to be the centerpiece of NET formation. However, in inflammatory conditions, oxygen 
concentration tends to be very low compared to the atmospheric oxygen concentration (21%). This 
parameter should be taken into account when investigating ROS-induced anti-microbial functions in 
vitro. In addition, increased pH has also been described as an enhancer of NI-NETs  
[122,123]. The authors explained the pH sensitive nature of NI-NETs by demonstrating that many 
key enzymes participating in NI-NET formation have an alkaline pH optimum. However, the authors 
did not investigate changes in energy metabolism in increased pH conditions. It is, however, known 
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and described in leukocytes that glycolysis is optimal at pH 7.5 and is enhanced in alkaline pH [124]. 
Overall, these reports clearly demonstrate the impact of environmental changes, such as pH on 
enhancing neutrophil key functions during inflammation.  
4.4. Metabolic Shift during Infection 
Metabolic shifts may occur at infectious sites in response to changes in the neutrophil 
microenvironment due to the presence of pathogens, rather than a result of neutrophil activation, as 
illustrated by the depletion of oxygen due to bacterial aerobic respiration [39] in comparison with 
neutrophil ROS production [125]. However, the concentrations of glucose or glutamine at infectious 
sites remain largely unknown so far. Since most changes in metabolism are linked to alterations in 
the carbon and nitrogen energy metabolism, understanding these changes will enable a better 
characterization of neutrophil adaptation to pathophysiological conditions. Some examples of 
metabolic modulation during infection will be discussed afterward. 
In general, intracellular bacteria trigger “host core defense mechanisms,” which consist of 
inducing the production of ROS and reactive nitrogen species. These core functions in host cells are 
controlled by NF-κB and are activated by pathogen-associated molecular patterns (PAMPs). Several 
PAMP-associated NF-κB targets are linked with metabolic reactions, such as heme oxygenase-1, Ca2+ 
transporters, divalent metal ions, adenosine- and adenosine-monophosphate deaminases, 
indolamine-2,3-dioxygenase, and upregulation of mitochondrial O2 respiration [126]. Besides NF-κB, 
another transcription factor, such as HIF-1, has also been linked to host defense mechanisms. 
Strikingly, the stabilization and activation of HIF-1 during infection was shown to be oxygen-
independent [127], which raises the question of intracellular oxygen availability during intracellular 
pathogen infection. In neutrophils, several intracellular pathogens have been shown to induce a “pro-
bacteria” metabolism. Francisella tularensis, which is the causative agent of tularemia, is able to inhibit 
neutrophil ROS production by secreting several acid phosphatases [128]. Similar acid phosphatases 
are produced by Coxiella burnetii and released via the T2SS, which causes a dramatic decrease in 
neutrophil NADPH oxidase and, thus, ROS production [129]. 
Besides modulating the intracellular compartment, many pathogens shape the extracellular 
infectious microenvironment. Together with glucose and other carbohydrate consumption, 
pathogens can also consume oxygen, which leads to a transition from inflammatory hypoxia to 
infectious hypoxia. Many oxygen-utilizing bacteria, such as E. coli, can utilize oxygen at nanomolar 
levels [130], which explains the severity of tissue hypoxia during infection.  
Infectious hypoxia was recently reviewed by Arena and colleagues [38]. In addition to resident 
host cells and infiltrating immune cells, bacteria also consume oxygen, which prevents its further use 
by neutrophil NADPH oxidase and illustrates the “battle for oxygen” occurring during bacterial 
infections. 
How and if tissue oxygenation and glutamine or glucose availability during infection can 
modulate the energy metabolism of neutrophils and other immune cells remains to be studied. It 
seems possible that a metabolic shift will occur not only upon arrival to the infectious inflammation 
site but also during inflammation, where the microenvironment may change. 
5. Importance of Metabolic Shifts in Neutrophil Population Heterogeneity 
In recent years, several observations had led to the understanding that neutrophils do not always 
form a homogenous population, especially in auto-immune disease and cancer. The identification 
and classification of different neutrophil subtypes together with immunometabolism has opened a 
new field of research discussed hereafter. 
5.1. Tumor-Associated Neutrophils  
Neutrophils are mostly associated with anti-tumoral functions, such as direct tumor cell killing 
and antigen presentation, which increases cytotoxic T lymphocyte-mediated anti-tumor immunity. 
However, it is now clear that neutrophils do not form a homogenous population and can play an 
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important role in tumor progression by impairing the activation of CD8+ T cells and enhancing tumor 
invasion through NETosis [131,132]. Two major neutrophil subpopulations have been intensively 
studied in the tumor microenvironment, which include tumor associated neutrophils (TANs) and 
myeloid-derived suppressor cells (MDSCs). First, defined in 2007 [133], MDSC are the most studied 
neutrophil-like cell population in cancer progression, present in great numbers in several cancer 
models [134–136]. It was first suggested that MDSCs are immature myeloid cells, able to differentiate 
into macrophages (tumor-associated macrophages, TAMs) or neutrophils (tumor-associated 
neutrophils, TANs) based on their myeloid origin (PMN-MDSCs and M-MDSCs). Metabolically, 
MDSCs are described as flexible, able to sense and adapt to different TMEs. For example, several 
studies point out the importance of lipid oxidative metabolism in these cells, especially in low glucose 
availability [137–139]. However, a recent publication challenges the link between lipid uptake and an 
energetic switch in MDSCs. Even if an upregulation of fatty acid transport protein 2 in PMN-MDSCs 
was observed, it did not lead to changes in the energy metabolism of MDSCs [140]. Nevertheless, it 
did increase the synthesis of prostaglandin E2 from arachidonic acid, contributing to the 
immunosuppressive activity of PMN-MDSCs [140]. 
Similar to macrophages, (M1 for anti-tumor and M2 for pro-tumor [5,6]) neutrophils are also 
reported to form two populations, N1 (anti-tumor/anti-inflammatory) and N2 (pro-tumor/pro-
inflammatory) [7]. Even if phenotypically different, there is no current marker to distinguish N1/N2 
neutrophils in the tumor micro-environment. 
The pro-inflammatory/pro-tumor neutrophils (N2), which are also called N2 TANs, are 
characterized by the release of excessive ROS, which enable cancer progression in several ways. Since 
increased ROS stabilizes HIF1, it promotes VEGF and MIF production, which are both important in 
cancer progression and chemotherapy resistance [141]. 
Because N2 TANs promote cancer metastasis to distant organs, they are now considered a 
potential therapeutic target. Currently, not much is known about the energy metabolism of TANs. 
However, similarities with tumor-associated macrophages (TAMs) can be drawn. 
In the tumor microenvironment, high numbers of M2 TAMs (pro-tumor/pro-inflammatory 
phenotype) is associated with tumor growth, metastasis, angiogenesis, and poor prognosis. It is 
progressively acknowledged that, because of their high plasticity, macrophages undergo metabolic 
changes that establish their functional fate. The metabolic shift toward the M2 phenotype in TAMs 
occurs when they accumulate in hypoxic areas of the tumor micro-environment [142]. In these 
conditions, TAMs will be exposed to lactic acid produced by the cancer cells, stabilizing HIF-1ɑ, even 
in the presence of increased oxygen levels [143]. Consequently, M2 TAMs will adapt to aerobic 
glycolysis, which is also known as the Warburg effect, a hallmark of cancer. 
Recent evidence suggests that not only do cancer cells modulate the metabolism of immune cells, 
but also immune cells, such as macrophages, enhance tumor hypoxia by depleting oxygen and 
secreting TNFɑ by inducing the glycolytic phenotype observed in tumors [142]. 
Although similarities have been drawn between PMN-MDSCs and N2 TANs, recent findings 
suggest otherwise. Results from transcriptomic analyses comparing MDSCs, TANs, and normal 
neutrophils revealed that MDSCs resemble more normal neutrophils, than TANs [145], which 
indicates that MDSCs and TANs are clearly two different populations with different mechanisms. 
Compared to MDCSs, TANs showed a lower expression of granule proteins and the NOX complex, 
which are both important for major neutrophil functions [145]. Recently, a new tumor-associated 
neutrophil population was described by Rice et al., the c-Kit+ tumor-elicited neutrophils (TENs) [146]. 
This subpopulation was characterized with the ability to use mitochondrial oxidative metabolism in 
low glucose availability. The authors showed that, in a limited glucose supply, TENs were able to use 
FAO-OxPHOS metabolism to maintain their NADPH supply, which is essential for ROS production.  
Another recent publication highlights the link between neutrophil mitochondria and motility in 
vivo [75]. The authors showed that, similar to cancer cells, migrating neutrophils have mitochondria 
localized in the front and in the rear, which could serve the purpose of localized ATP production. 
Bao and colleagues, however, demonstrated that, although neutrophils produce most of their ATP 
via glycolysis, mitochondria are essential for producing the ATP that triggers their activation via a 
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purinergic signaling process [147]. They observed that external stimulation of neutrophils with fMPL 
increased the ∆Ψm and released ATP, which leads to Ca2+ mobilization and oxidative burst.  
5.2. Low-Density Neutrophils 
Low-density neutrophils (LDNs) are a population of neutrophils obtained from the PBMC 
(peripheral blood mononuclear cells) fraction after density gradient centrifugation. LDNs are 
currently divided into two subpopulations, which include the immunosuppressive LDNs, mainly 
found in cancer, pregnancy, infections, and systemic inflammation; and the proinflammatory LDNs, 
mainly found in autoimmune diseases, such as systemic lupus erythematosus and anti-neutrophil 
cytoplasmic autoantibody (ANCA) vascularitis, and often referred to as low density granulocytes 
(LDGs).  
Although LDNs have been found in many tumor microenvironments, their presence in liver 
metastasis seems to be the most relevant [148]. Recently, Hsu et al. showed that cancer-cell-produced 
granulocyte colony-stimulating factor (G-CSF) was involved in the mobilization of immature low-
density neutrophils (iLDNs), which promote extensive liver metastasis. These immature cells 
constitute another subpopulation of LDNs found in several disease models. Mature LDNs, however, 
seemed to inhibit the formation of liver metastases. In liver metastases, iLDNs were shown to 
engaged in mitochondrial-dependent ATP production and were able to perform NETosis under 
nutrient-deprived conditions (without glucose). This is uncommon since NETosis has been reported 
to rely strongly on glucose availability in mature neutrophils [114]. The authors reported that iLDNs 
relied on the catabolism of glutamate and proline to support mitochondrial-dependent metabolism 
in the absence of glucose. 
With some exception discussed previously, not much is known about tumor/metastasis-
promoting neutrophils. Since similarities are drawn between TAMs and neutrophil-like tumor 
promoting cells (PMN-MDCSs, TANs, TENs, LDNs), the question regarding if neutrophils serve a 
similar purpose in the tumor microenvironment remains uncertain. 
Taken together, it seems like tumor-promoting neutrophils are metabolically more flexible than 
circulating neutrophils, which enables them to adapt in situ to different tumor micro-environments. 
Int. J. Mol. Sci. 2020, 21, 287 15 of 23 
 
 
Figure 2. Metabolic pathways in non-activated (A) and activated neutrophils (B).  
G6P—Glucose-6-phosphate; PPP—Pentose Phosphate Pathway; GLUT1—Glucose Transporter 1; 
SLC—Solute Carrier; OXPHOS—Oxidative Phosphorylation; G3P—Glycerol-3-Phosphate;  
F6P—Fructose-6-Phosphate; FAO—Fatty Acid Oxidation; TCA—Tricarboxylic Acid Cycle;  
NOX—NADPH Oxidase; ER—Endoplasmic Reticulum; NETs—Neutrophil Extracellular Traps. 
6. Conclusions 
Neutrophil metabolism plays a central role in their survival in changing environments 
encountered during their life cycle beginning from their development to the activation of their 
antimicrobial functions. Neutrophil metabolism dysregulation has been observed in many 
inflammatory diseases such as diabetes, sepsis, cystic fibrosis, lupus, or atherosclerosis [149]. The link 
between metabolism modulation and several activation pathways has been established in many 
reports. However, no direct link has been established with changes of their micro-environment and 
the availability of key metabolites such as glucose, glutamine, and oxygen. Major efforts should be 
A 
B 
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made in the future to assess local micro-environmental changes, which requires the development of 
new and non-disruptive methods to perform quantification in situ. As outlined in Figure 1 and Table 
1, knowledge remains scarce in pathophysiological conditions. It has to be highlighted in this section 
that, without these data, any attempt to validate the relevance of neutrophil metabolic adaptation in 
health and diseases will be challenging. 
Most of the recent studies are aimed at describing the impact of neutrophil metabolic shifts on 
neutrophil survival and activation. However, the impact of neutrophil activation on neutrophil 
metabolic shift induction should also be considered, even though it remains largely unexplored. This 
idea may be supported by the fact that neutrophil metabolic activity and activation may differentially 
“imprint” their microenvironment (oxygen availability, pH, glucose, or glutamine concentration), 
potentially leading to secondary metabolic shifts. As a consequence, the contribution of neutrophil 
metabolic shifts in the neutrophil lifecycle has likely been underestimated so far and, thus, represents 
an attractive emerging field of research. It is anticipated that neutrophil metabolic shifts will be 
different in inflammatory and infectious diseases and may be considered in the future as a specific 
“signature” for the development of the pathology. Further investigations are urgently needed to fully 
understand how neutrophils adapt to their microenvironment and to decipher to which extent their 
metabolic shifts impact the outcome of inflammatory diseases, to envision new therapy strategies. 
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